ImmunityBio(US:IBRX) Businesswire·2026-01-16 12:00Core Insights - ImmunityBio, Inc. announced updated efficacy and safety results from the QUILT-106 clinical study, evaluating an off-the-shelf allogeneic CD19 CAR-NK therapy combined with rituximab for patients with Waldenström Non-Hodgkin lymphoma, showing promising results in disease control and remission duration [1][2][5] Efficacy and Safety Results - The updated follow-up indicates sustained complete responses lasting up to 15 months, with 100% disease control observed to date [2][3] - Four patients have been enrolled in the study, all maintaining clinical disease control, with two patients showing durable complete remission at 7 and 15 months, respectively [3][4] - The therapy demonstrated rapid onset of complete remission after only two cycles, highlighting the potential for long-term immune-mediated disease control without continuous therapy [4][5] Treatment Protocol - Patients received a total of eight doses of cell therapy in an outpatient setting without lymphodepletion, targeting tumors with both CD19 and CD20 immunotherapies [2][7] - The regimen involved infusing CD19 CAR NK cells with rituximab, administered as two doses per cycle every 21 days for a total of four cycles [2][7] Unique Treatment Approach - This represents the first chemotherapy-free and lymphodepletion-free immunotherapy regimen combining off-the-shelf allogeneic CD19 CAR-NK cells with rituximab, achieving 100% disease control in Waldenström Non-Hodgkin lymphoma [7][8] - The outpatient administration eliminates the need for cytotoxic conditioning and inpatient hospitalization, addressing limitations associated with conventional CAR-T therapies [7][8] Future Directions - Enrollment and follow-up in QUILT-106 are ongoing, with additional clinical updates expected as more patients become evaluable [9] - A follow-up study is being designed to test the combination of NK-CAR with ANKTIVA and rituximab to build on the success of QUILT-106 in treating indolent lymphoma [10]